First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

January 7, 2024

Study Completion Date

March 4, 2024

Conditions
Glioblastoma, Adult
Interventions
BIOLOGICAL

Multiple dose of EO2401

Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase

Trial Locations (10)

8908

Institit Catala D'Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat

21000

Centre Georges François Leclerc, Dijon

53105

Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn, Bonn

60528

Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main

68167

Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim

69120

Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg, Heidelberg

72076

Zentrum für Neuroonkologie Universitätsklinikum Tübingen, Tübingen

75013

Hôpital Pitié-Salpétrière, Paris

02215

Dana Farber Cancer Institute, Boston

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Enterome

INDUSTRY